Related references
Note: Only part of the references are listed.Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer
Fenlai Tan et al.
FUTURE ONCOLOGY (2015)
Severe Acute Interstitial Lung Disease After Crizotinib Therapy in a Patient With EML4-ALK-Positive Non-Small-Cell Lung Cancer
Akihiro Tamiya et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
Yuankai Shi et al.
LANCET ONCOLOGY (2013)
Targeting the Epidermal Growth Factor Receptor in Solid Tumor Malignancies
Mette K. Nedergaard et al.
BIODRUGS (2012)
Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors
Shaojing Hu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Synthesis and Evaluation of Some Coumarin Based Schiff's Bases as Potential Antimicrobial Agents'
Vishakha Bansode et al.
E-JOURNAL OF CHEMISTRY (2012)
Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies
Fenlai Tan et al.
LUNG CANCER (2012)
Human Metabolism of Lapatinib, a Dual Kinase Inhibitor: Implications for Hepatotoxicity
Stephen Castellino et al.
DRUG METABOLISM AND DISPOSITION (2012)
F-18 Labeled benzimidazole derivatives as potential radiotracer for positron emission tomography (PET) tumor imaging
Shuting Zhang et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2010)
Positron Emission Tomography (PET) Imaging with [11C]-Labeled Erlotinib: A Micro-PET Study on Mice with Lung Tumor Xenografts
Ashfaque A. Memon et al.
CANCER RESEARCH (2009)
Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer (vol 27, pg 1948, 2009)
D. J. Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Aminoquinazolines as TRPV1 antagonists: Modulation of drug-like properties through the exploration of 2-position substitution
Charles A. Blum et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Evaluation of [F-18]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors
Helen Su et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial
Ulrich Gatzemeier et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors
Galith Abourbeh et al.
NUCLEAR MEDICINE AND BIOLOGY (2007)
TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
HA Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Potential 18F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase
TA Bonasera et al.
NUCLEAR MEDICINE AND BIOLOGY (2001)
Share Paper
